^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Folate receptor 1-targeted antibody-drug conjugate

    Related drugs:
    Apply
    First in Human Study of IMGN151 in Recurrent Gynaecological Cancers (IMGN151-1001) (NCT05527184)
    Phase 1
    AbbVie
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    01/11/2023
    Primary completion :
    02/01/2027
    Completion :
    02/01/2027
    FOLR1
    |
    opugotamig olatansine (IMGN-151)
    An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib (NCT05887609)
    Phase 2
    University of Colorado, Denver
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    10/03/2023
    Primary completion :
    04/15/2026
    Completion :
    12/01/2027
    BRCA
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Elahere (mirvetuximab soravtansine-gynx)
    Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCI-2018-00438) (NCT03552471)
    Phase 1
    Ohio State University Comprehensive Cancer Center
    Completed
    Last update posted :
    02/13/2025
    Initiation :
    07/12/2018
    Primary completion :
    06/24/2022
    Completion :
    12/19/2022
    BRCA
    |
    BRCA mutation
    |
    Rubraca (rucaparib) • Elahere (mirvetuximab soravtansine-gynx)
    Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer (NCT05456685)
    Phase 2
    AbbVie
    Active, not recruiting
    Last update posted :
    01/30/2025
    Initiation :
    09/28/2022
    Primary completion :
    05/12/2026
    Completion :
    05/12/2026
    FOLR1 • BRCA
    |
    FOLR1 expression
    |
    carboplatin • Elahere (mirvetuximab soravtansine-gynx)
    A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types (MORAb-202-G000-201) (NCT04300556)
    Phase 1/2
    Eisai Inc.
    Recruiting
    Last update posted :
    12/09/2024
    Initiation :
    08/06/2020
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    HER-2 • BRAF • ER • ALK • PGR • ROS1
    |
    HER-2 negative
    |
    Halaven (eribulin mesylate) • prednisone • dexamethasone • farletuzumab ecteribulin (MORAb-202) • farletuzumab (MORAB-003) • prednisolone
    A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (CA116-001) (NCT05613088)
    Phase 2
    Bristol-Myers Squibb
    Active, not recruiting
    Last update posted :
    11/21/2024
    Initiation :
    02/01/2023
    Primary completion :
    06/05/2024
    Completion :
    10/11/2026
    FOLR1
    |
    paclitaxel • pegylated liposomal doxorubicin • topotecan • farletuzumab ecteribulin (MORAb-202)
    A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) (NCT03835819)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    11/08/2024
    Initiation :
    01/02/2020
    Primary completion :
    06/04/2024
    Completion :
    05/01/2027
    FOLR1 • MLH1 • MSH6 • MSH2
    |
    MSH6 expression
    |
    Keytruda (pembrolizumab) • Elahere (mirvetuximab soravtansine-gynx)
    Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer (NCT03832361)
    Phase 2
    Alessandro Santin
    Recruiting
    Last update posted :
    08/20/2024
    Initiation :
    07/15/2020
    Primary completion :
    10/01/2025
    Completion :
    10/01/2028
    FOLR1
    |
    Elahere (mirvetuximab soravtansine-gynx)
    Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer (KEYNOTE PN409) (NCT02606305)
    Phase 1/2
    ImmunoGen, Inc.
    Completed
    Last update posted :
    06/14/2024
    Initiation :
    03/02/2016
    Primary completion :
    03/12/2021
    Completion :
    03/12/2021
    FOLR1
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx)
    Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) (NCT05445778)
    Phase 3
    ImmunoGen, Inc.
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    12/27/2022
    Primary completion :
    03/01/2027
    Completion :
    04/01/2029
    FOLR1 • BRCA • MUC16
    |
    FOLR1 expression • MUC16 elevation
    |
    Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
    PRO1184 for Advanced Solid Tumors (PRO1184-001) (NCT05579366)
    Phase 1/2
    ProfoundBio US Co.
    Recruiting
    Last update posted :
    05/03/2024
    Initiation :
    12/07/2022
    Primary completion :
    10/01/2025
    Completion :
    04/01/2026
    HER-2 • FOLR1
    |
    HR positive • HER-2 negative • FOLR1 expression • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • rinatabart sesutecan (PRO1184)
    Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO) (NCT05041257)
    Phase 2
    ImmunoGen, Inc.
    Active, not recruiting
    Last update posted :
    04/22/2024
    Initiation :
    08/31/2021
    Primary completion :
    01/17/2024
    Completion :
    12/13/2024
    FOLR1 • BRCA
    |
    FOLR1 expression • BRCA mutation
    |
    Elahere (mirvetuximab soravtansine-gynx)
    REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 (NCT05870748)
    Phase 2/3
    Sutro Biopharma, Inc.
    Recruiting
    Last update posted :
    04/19/2024
    Initiation :
    07/12/2023
    Primary completion :
    09/01/2025
    Completion :
    02/01/2026
    FOLR1
    |
    FOLR1 expression • FOLR1 positive
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • luveltamab tazevibulin (STRO-002) • Neulasta (pegfilgrastim)
    Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer (NCI-2016-01913) (NCT02996825)
    Phase 1
    City of Hope Medical Center
    Completed
    Last update posted :
    04/02/2024
    Initiation :
    03/22/2017
    Primary completion :
    02/09/2024
    Completion :
    02/09/2024
    HER-2 • ER • PGR • MUC16
    |
    HER-2 negative • PGR expression
    |
    gemcitabine • Elahere (mirvetuximab soravtansine-gynx) • liposomal gemcitabine (FF-10832)
    Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer (MIROVA) (NCT04274426)
    Phase 2
    AGO Research GmbH
    Recruiting
    Last update posted :
    01/15/2024
    Initiation :
    10/13/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    BRCA1 • BRCA2 • FOLR1 • MUC16
    |
    BRCA2 mutation • BRCA1 mutation • BRCA wild-type
    |
    carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • doxorubicin liposomal
    Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection (NCT05378737)
    Phase 1
    Bio-Thera Solutions
    Recruiting
    Last update posted :
    12/22/2023
    Initiation :
    07/06/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    FOLR1
    |
    FOLR1 expression
    Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT04606914)
    Phase 2
    University of Alabama at Birmingham
    Recruiting
    Last update posted :
    11/30/2023
    Initiation :
    05/27/2021
    Primary completion :
    05/31/2026
    Completion :
    05/31/2028
    BRCA
    |
    FOLR1 expression
    |
    carboplatin • Elahere (mirvetuximab soravtansine-gynx)
    A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL) (NCT04209855)
    Phase 3
    ImmunoGen, Inc.
    Active, not recruiting
    Last update posted :
    03/06/2023
    Initiation :
    12/31/2019
    Primary completion :
    09/01/2023
    Completion :
    04/01/2024
    FOLR1
    |
    FOLR1 expression
    |
    paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • doxorubicin liposomal
    A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors (MORAb-202-J081-101) (NCT03386942)
    Phase 1
    Eisai Inc.
    Completed
    Last update posted :
    11/28/2022
    Initiation :
    11/28/2017
    Primary completion :
    10/26/2022
    Completion :
    10/26/2022
    BRAF • ALK
    |
    BRAF V600E • BRAF V600
    |
    Halaven (eribulin mesylate) • farletuzumab ecteribulin (MORAb-202) • farletuzumab (MORAB-003)
    A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer (NCT05622890)
    Phase 3
    Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    11/21/2022
    Initiation :
    08/18/2022
    Primary completion :
    04/30/2023
    Completion :
    12/31/2023
    FOLR1 • MUC16
    |
    Elahere (mirvetuximab soravtansine-gynx)
    First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors (IMGN-0401) (NCT01609556)
    Phase 1
    ImmunoGen, Inc.
    Completed
    Last update posted :
    02/17/2021
    Initiation :
    06/28/2012
    Primary completion :
    03/19/2018
    Completion :
    03/19/2018
    FOLR1
    |
    Elahere (mirvetuximab soravtansine-gynx)
    Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer (NCT03106077)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    12/02/2020
    Initiation :
    06/05/2017
    Primary completion :
    10/01/2019
    Completion :
    10/01/2019
    HER-2 • ER • PGR
    |
    Elahere (mirvetuximab soravtansine-gynx)
    A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (FORWARD I) (NCT02631876)
    Phase 3
    ImmunoGen, Inc.
    Completed
    Last update posted :
    10/14/2020
    Initiation :
    03/02/2016
    Primary completion :
    01/01/2019
    Completion :
    01/01/2020
    FOLR1
    |
    FOLR1 positive
    |
    paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • doxorubicin liposomal
    Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer (NCT03836157)
    Phase 2
    University of Oklahoma
    Withdrawn
    Last update posted :
    06/27/2019
    Initiation :
    05/31/2019
    Primary completion :
    11/30/2021
    Completion :
    05/01/2022
    FOLR1
    |
    Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)